Cancer Vaccines

With the first therapeutic cancer vaccine approved by the FDA in April 2010, and other vaccines currently in the pipeline, the interest in this developing area is set to increase exponentially. Breaking new grounds,Cancer Vaccines provides a state of the art perspective on a projected, rapidly growing field, and describes the successful journey of the first licensed therapeutic vaccines for cancer, from design to approval. Written and edited by key personnel in industry and academia working within cancer vaccines development, this book is the result of a global collaborative effort integrating industry, academia, non-for profit, with participation from members of regulatory agencies. Key features: * Highlights major vaccines and platform technologies in early or late development, nearing approval * Introduces emerging technologies that could yield novel classes of drugs bridging active and passive immunotherapies * Provides an update of pipeline and approved cancer vaccines * Encompasses both scientific, translational as well as development aspects * Includes an introductory chapter on the immune systems role in cancer and a closing chapter on the challenges involved in cancer vaccine development An essential read for: * Cancer immunologists in academia and industry * Drug developers in the area of oncology biotherapies * Clinical physicians involved in clinical trials of cancer biotherapies * Regulatory agencies CONTENTS 1. 1. Introduction: Cancer vaccines: mechanism and a clinical overview Antoni Ribas and Adrian Bot 2. 2. Revisiting the paradigm on the putative need for antigen-specific responses in cancer Gail D. Sckisel, Julia K. Tietze, and William J. Murphy VACCINE PLATFORMS FOR GENITO-URINARY CANCERS, WITH POTENTIAL APPLICABILITY TO OTHER TUMORS 3. 3. Development of novel immune interventions for genito-urinary cancers Neeraj Agarwal and Nicholas J. Vogelzang 4. 4. Autologous cellular immunotherapy in late-stage prostate cancer: The development history of sipuleucel-T (PROVENGE®) David L. Urdal and Mark W. Frohlich 5. 5. Design, development and translation of poxvirus-based vaccines for cancer Benedetto Farsaci, Anna Kwilas, and James W. Hodge VACCINES FOR SOLID CANCERS AND HEMATOLOGICAL MALIGNANCIES 6. 6. Of mice and men (and dogs!): The first approved cancer therapy vaccine Philip J. Bergman and Jedd D. Wolchok 7. 7. Recombinant protein vaccination for antigen-specific cancer immunotherapy Pedro de Sousa Alves and Vincent Brichard 8. 8. Antigen-targeted, synthetic vaccines for metastatic cancer Zhiyong Qiu, David C. Diamond, Kent A. Smith, Dar Rosario, Sabrina Miles, Mihail Obrocea, Thomas M. Kundig and Adrian Bot 9. 9. Clinical perspectives in cancer vaccines for hematological diseases Maurizio Chiriva-Internati, Leonardo Mirandola, Marjorie Jenkins, Martin Cannon, Everardo Cobos, and W. Martin Kast 10. Epitope-based vaccines for cancer Vy Phan-Lai, Denise L. Cecil, Gregory E. Holt, Daniel R. Herendeen, Forrest Kievit, Miqin Zhang, and Mary L. Disis VACCINE DEVELOPMENT: TRIAL DESIGN AND IMMUNE ASSAYS 11. 11. Emerging clinical trial design concepts for therapeutic cancer vaccines Christina Musselli, Leah Isakov, and Kerry Wentworth 12. 12. T-cell immune monitoring assays to guide the development of new cancer vaccines Cedrik M. Britten, Sylvia Janetzki, Cecile Gouttefangeas, Marij J.P. Welters, Michael Kalos, Christian Ottensmeier, Axel Hoos, and Sjoerd H. van der Burg 13. 13. A biomarker-based, systems biology approach guiding the development of active immunotherapies and immune monitoring Glenda Canderan, Peter Wilkinson, John Schatzle, Mark Cameron, and Rafick-Pierre Sékaly EMERGING NEW VACCINE STRATEGIES, TARGETS, AND ADJUVANTS 14. 14. Targeting regulatory T cells and other strategies to enable cancer vaccines Christopher Paustian, Shawn M. Jensen, Sarah Church, Sachin Puri, Chris Twitty, Hong-Ming Hu, Brendan D. Curti, Walter J. Urba, Raj K. Puri and Bernard A. Fox 15. 15. Molecular targeting of cancer stem cells Zhenhua Li, Debraj Mukherjee, Jang-Won Lee, and John S. Yu 16. 16. RNA in cancer vaccine therapy Smita Nair, David Boczkowski, Scott Pruitt, and Johannes Urban 17. 17. Induction of innate immunity by nucleic acids: A potential adjuvant for cancer vaccines? Bo Jin and Anthony E.T. Yeo NEXT-GENERATION HYBRID ACTIVE/PASSIVE IMMUNOTHERAPIES 18. 18. Passive immunotherapy by T cell-engaging bispecific antibodies Patrick A. Baeuerle and Benno Rattel 19. 19. Antibodies to peptide-HLA complexes have potential application for cancer diagnosis and therapy Jon A. Weidanz and William H. Hildebrand